Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Axel Florschütz"'
Autor:
Carsten Hirt, Eva Hoster, Michael Unterhalt, Mathias Hänel, Gabriele Prange-Krex, Roswitha Forstpointner, Axel Florschütz, Ullrich Graeven, Norbert Frickhofen, Gerald Wulf, Eva Lengfelder, Christian Lerchenmüller, Rudolf Schlag, Judith Dierlamm, Ludwig Fischer von Weikersthal, Asima Ahmed, Hanns-Detlev Harich, Andreas Rosenwald, Wolfram Klapper, Martin Dreyling, Wolfgang Hiddemann, Michael Herold
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e600 (2021)
The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus
Externí odkaz:
https://doaj.org/article/7f58ca3174b5414e8506396f6d40af2b
Autor:
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Krämer, Christian Junghanss, Lars-Olof Mügge, Detlev Hähling, Carsten Hirt, Christian Späth, Norma Peter, Bernhard Opitz, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Pönisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schütte, Ralph Naumann, Hartmut Eimermacher, Bernd Dörken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Wörmann, Carsten Müller-Tidow, Hubert Serve, Christoph Schliemann, Rüdiger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, Verena S. Hoffmann
Publikováno v:
Annals of Hematology. 102:547-561
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arm
Autor:
Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Sanne Tonino, Marcel Kap, Roberto D Liu, Martine E.D. Chamuleau, Hein P.J. Visser, Eva De Jongh, Erik WAF Marijt, Maria B.L. Leijs, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd J.F. Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Maria Cuijpers, Lara H. Böhmer, Lidwine W. Tick, Axel Florschütz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne IJ Arens, Gerben JC Zwezerijnen, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
Publikováno v:
Blood. 140:2283-2285
Autor:
Hans-Heinrich Wolf, Michael Cross, Kolja Reifenrath, Detlev Hähling, Rainer Krahl, Georg Maschmeyer, Thomas Fischer, Späth Christian, Christoph Kahl, Dietger Niederwieser, Christian Junghanss, Schmidt Volker, Antje Schulze, Thomas Heinicke, Niklas Zojer, Herbert G. Sayer, Haifa Kathrin Al-Ali, Axel Florschütz, Norma Peter, Andreas Hochhaus, Sebastian Scholl, Ute Hegenbart
Publikováno v:
Annals of Hematology
Ann Hematol
Ann Hematol
Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1
Autor:
Thomas J. Ettrich, Jens Atzpodien, Stephan Kanzler, Swen Wessendorf, Swantje Held, Petra Buechner-Steudel, Axel Florschütz, D Nörenberg, Max Seidensticker, Anke Reinacher-Schick, Jorge Riera-Knorrenschild, Dominik Paul Modest, Michael Geissler, J. Greeve, Uwe M. Martens, Volker Heinemann, Sebastian Stintzing, Andrea Tannapfel, Annika Kurreck, Thomas Seufferlein
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and post-DpR survival as relevant endpoints. Methods We analyzed DpR by central review of compute
Autor:
Uwe M. Martens, Swen Wessendorf, Heinemann, Petra Buechner-Steudel, J. Greeve, Axel Florschütz, Thomas J. Ettrich, Andrea Tannapfel, Anke Reinacher-Schick, Thomas Seufferlein, Michael Geissler, Swantje Held, Jens Atzpodien, Jens Ricke, Max Seidensticker, Jorge Riera-Knorrenschild, Stephan Kanzler, Dominik Paul Modest, Dominik Nörenberg
Publikováno v:
Journal of Clinical Oncology. 37:3401-3411
PURPOSE This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreated
Autor:
Thomas Heinicke, Rainer Krahl, Christoph Kahl, Michael Cross, Sebastian Scholl, Hans‑Heinrich Wolf, Detlev Hähling, Ute Hegenbart, Norma Peter, Antje Schulze, Axel Florschütz, Volker Schmidt, Kolja Reifenrath, Niklas Zojer, Christian Junghanss, Herbert G. Sayer, Georg Maschmeyer, Christian Späth, Andreas Hochhaus, Thomas Fischer, Haifa Kathrin Al‑Ali, Dietger Niederwieser
Publikováno v:
Annals of Hematology. 100:2877-2878
Autor:
Michael Koehler, Susanne Hoppe, Siegfried Kropf, Anke Lux, Rainer Bartsch, Bernhard Holzner, Juergen Krauter, Axel Florschütz, Kathleen Jentsch-Ullrich, Joerg Frommer, Hans-Henning Flechtner, Thomas Fischer
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN.
Background: Cancer regularly disrupts health and developmental trajectories in adolescents and young adults (AYAs). Parents have been shown to have a substantial impact on the health and cancer survivorship activities of AYA patients in the form of s
Autor:
Dominik P, Modest, Uwe M, Martens, Jorge, Riera-Knorrenschild, Jobst, Greeve, Axel, Florschütz, Swen, Wessendorf, Thomas, Ettrich, Stephan, Kanzler, Dominik, Nörenberg, Jens, Ricke, Max, Seidensticker, Swantje, Held, Petra, Buechner-Steudel, Jens, Atzpodien, Volker, Heinemann, Thomas, Seufferlein, Andrea, Tannapfel, Anke C, Reinacher-Schick, Michael, Geissler
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(35)
This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreatedThe prima
Autor:
Ievgen Glavynskyi, Steffen Frenzel, Diogo Cruz, Jochen Winter, Kristian Weissenberg, Thomas Wild, Axel Florschütz
Publikováno v:
The Journal of Hand Surgery. 46:74.e1-74.e8
Chronic lymphocytic leukemia (CLL) involving the hand, especially with bone involvement, is extremely rare. We report a case of a 62-year-old man, with a 4-year history of a subclinical CLL, presenting with chronic swelling and pain over the dorsal s